Nothing Special   »   [go: up one dir, main page]

HUP0100586A2 - Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények - Google Patents

Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények

Info

Publication number
HUP0100586A2
HUP0100586A2 HU0100586A HUP0100586A HUP0100586A2 HU P0100586 A2 HUP0100586 A2 HU P0100586A2 HU 0100586 A HU0100586 A HU 0100586A HU P0100586 A HUP0100586 A HU P0100586A HU P0100586 A2 HUP0100586 A2 HU P0100586A2
Authority
HU
Hungary
Prior art keywords
urinary tract
lower urinary
tract symptoms
pharmaceutical compositions
treating lower
Prior art date
Application number
HU0100586A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22663745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100586(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0100586D0 publication Critical patent/HU0100586D0/hu
Publication of HUP0100586A2 publication Critical patent/HUP0100586A2/hu
Publication of HUP0100586A3 publication Critical patent/HUP0100586A3/hu
Publication of HU230982B1 publication Critical patent/HU230982B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány férfiakban jóindulatú prosztata-hiperpláziával kapcsolatosalsó húgyúti tünetek kezelésére alkalmas gyógyászati készítményekrevonatkozik, melyek alfa-adrenoreceptor antagonistát és muszkarinantagonistát tartalmaznak. A találmány szerinti készítmények különösenalkalmasak mérsékelt vagy súlyos alsó húgyúti tünetek kezelésére. Ó
HU0100586A 2000-02-09 2001-02-06 Alsó húgyúti tünetek kezelésére alkalmas, egy alfa-adrenoreceptor antagonistát és darifenacint tartalmazó gyógyászati készítmények HU230982B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18131000P 2000-02-09 2000-02-09
US60/181,310 2000-02-09

Publications (4)

Publication Number Publication Date
HU0100586D0 HU0100586D0 (en) 2001-03-28
HUP0100586A2 true HUP0100586A2 (hu) 2001-11-28
HUP0100586A3 HUP0100586A3 (en) 2003-05-28
HU230982B1 HU230982B1 (hu) 2019-08-28

Family

ID=22663745

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100586A HU230982B1 (hu) 2000-02-09 2001-02-06 Alsó húgyúti tünetek kezelésére alkalmas, egy alfa-adrenoreceptor antagonistát és darifenacint tartalmazó gyógyászati készítmények

Country Status (12)

Country Link
US (2) US20010044438A1 (hu)
EP (2) EP2266571A1 (hu)
KR (2) KR20010078803A (hu)
AU (3) AU1832901A (hu)
CA (1) CA2334460C (hu)
HU (1) HU230982B1 (hu)
IL (1) IL141235A (hu)
MY (1) MY164900A (hu)
NZ (1) NZ509807A (hu)
PE (1) PE20011167A1 (hu)
TW (1) TWI287448B (hu)
ZA (1) ZA200101012B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
CN1298317C (zh) * 2001-11-07 2007-02-07 斯索恩有限公司 坦洛新片剂
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1552825A4 (en) * 2002-06-07 2009-11-25 Astellas Pharma Inc THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
AU2003260373B2 (en) * 2002-08-14 2008-02-21 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
WO2004071533A1 (ja) * 2003-02-14 2004-08-26 Takeda Pharmaceutical Company Limited 局所投与用製剤
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
WO2007010509A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
AU2006327882A1 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
EP2172201A4 (en) * 2007-07-20 2011-07-06 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US7891492B2 (en) * 2007-08-13 2011-02-22 Carton Service, Incorporated Pharmaceutical blister card package
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
LT2451445T (lt) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
EP4035668A1 (en) 2012-09-05 2022-08-03 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN111093648A (zh) 2017-07-20 2020-05-01 艾伦实验室股份有限公司 治疗近视的组合物和方法
WO2024107961A1 (en) * 2022-11-17 2024-05-23 Dri Biosciences Corporation Compositions and methods of treating neurological conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
WO1994009785A2 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
MY164900A (en) 2018-01-30
KR20010078803A (ko) 2001-08-21
CA2334460C (en) 2009-01-27
AU2009227918B2 (en) 2011-09-22
TWI287448B (en) 2007-10-01
HU230982B1 (hu) 2019-08-28
CA2334460A1 (en) 2001-08-09
US7138405B2 (en) 2006-11-21
HU0100586D0 (en) 2001-03-28
ZA200101012B (en) 2002-08-06
NZ509807A (en) 2002-09-27
EP1123705A1 (en) 2001-08-16
IL141235A0 (en) 2011-08-01
AU2009227918A1 (en) 2009-11-12
HUP0100586A3 (en) 2003-05-28
AU2006202176A1 (en) 2006-06-15
US20050222165A1 (en) 2005-10-06
IL141235A (en) 2012-04-30
KR20040032141A (ko) 2004-04-14
US20010044438A1 (en) 2001-11-22
PE20011167A1 (es) 2001-11-13
EP2266571A1 (en) 2010-12-29
AU1832901A (en) 2001-08-16

Similar Documents

Publication Publication Date Title
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
WO2006018743A3 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
BR0109931A (pt) Composições farmacêuticas
SG166106A1 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
BG105302A (en) Means for improving cognition
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
TNSN07240A1 (en) Compounds for flaviviridae treatment
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
EP1743656A3 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
SE0001916D0 (sv) Novel formulation
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERUS LABS LUXCO SARL, LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

HC9A Change of name, address

Owner name: MERUS LABS LUXCO SARL, LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

GB9A Succession in title

Owner name: MERUS LABS LUXCO II S.A R.L., LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; MERUS LABS LUXCO SARL, LU; MERUS LABS LUXCO SARL, LU; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

HC9A Change of name, address

Owner name: MERUS LABS LUXCO II S.A R.L., LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; MERUS LABS LUXCO SARL, LU; MERUS LABS LUXCO SARL, LU; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

MM4A Lapse of definitive patent protection due to non-payment of fees